Endocrinology, Vol 120, 549-558, Copyright © 1987 by Endocrine Society

ARTICLES

Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays

M Ozturk, D Bellet, L Manil, G Hennen, R Frydman and J Wands

Several libraries of monoclonal antibodies have been produced against epitopes that reside on hCG, alpha hCG, and beta hCG. Having characterized them physically, we explored their use in the construction of highly specific and sensitive immunoradiometric assays. There were several important immunochemical considerations with respect to developing assays that accurately detect low levels of free subunits in serum in the presence of high concentrations of the native hormone. These include physical properties and specificities of the monoclonal antibodies, choice of capture antibody on the solid phase support, assay design, and purity of hormone standards. Using such assays, we found early pregnancy (in vitro fertilization) to be characterized by the sequential appearance of hCG, followed by beta hCG and then alpha hCG. Molar ratios of beta hCG to alpha hCG and beta hCG to hCG were highest in early gestation. However, there was a reversal of the beta hCG to alpha hCG ratio at 12-13 weeks gestation, and an excess of free alpha hCG was observed thereafter. Except for values obtained in very early pregnancy, the beta hCG to hCG ratio remained remarkably constant at approximately 0.5% throughout gestation. In contrast, choriocarcinoma was distinguished by absolute serum beta hCG concentrations 3-100 times greater than the maximum values observed during pregnancy and, more importantly, by exceedingly high beta hCG to hCG ratios. For comparison, we studied hCG, alpha hCG, and beta hCG levels in an additional 178 patients with nontrophoblastic tumors. Ectopic production of alpha hCG and beta hCG was rare (3%), and thus far, we have been unable to demonstrate the presence of hCG in such patients. Therefore, hCG and the free subunits appear not to be useful as serological markers for nontrophoblastic tumors.

This article has been cited by other articles:

				U.-H. Stenman, A. Tiitinen, H. Alfthan, and L. Valmu The classification, functions and clinical use of different isoforms of HCG Hum. Reprod. Update, November 1, 2006; 12(6): 769 - 784. [Abstract] [Full Text] [PDF]

				P. Pautier, S. Ghione, S. Brailly-Tabard, C. Lhomme, P. Morice, and J.M. Bidart Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy? Hum. Reprod., November 1, 2001; 16(11): 2434 - 2437. [Abstract] [Full Text] [PDF]

				A. Tarrade, K. Schoonjans, J. Guibourdenche, J. M. Bidart, M. Vidaud, J. Auwerx, C. Rochette-Egly, and D. Evain-Brion PPAR{gamma}/RXR{alpha} Heterodimers Are Involved in Human CG{beta} Synthesis and Human Trophoblast Differentiation Endocrinology, October 1, 2001; 142(10): 4504 - 4514. [Abstract] [Full Text] [PDF]

				W. J. Walton, V. T. Nguyen, V. Y. Butnev, V. Singh, W. T. Moore, and G. R. Bousfield Characterization of Human FSH Isoforms Reveals a Nonglycosylated {beta}-Subunit in Addition to the Conventional Glycosylated {beta}-Subunit J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3675 - 3685. [Abstract] [Full Text] [PDF]

				B. Couzinet, J. Pantel, P. Chanson, J. Young, S. Brailly, I. T. Huhtaniemi, J.-M. Bidart, and G. Schaison Measurement of Plasma Free Luteinizing Hormone {beta}-Subunit in Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2293 - 2298. [Abstract] [Full Text]

				I. Cedrin-Durnerin, J.-M. Bidart, P. Robert, J.-P. Wolf, M. Uzan, and J.-N. Hugues Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization Hum. Reprod., May 1, 2000; 15(5): 1009 - 1014. [Abstract] [Full Text] [PDF]

				E. Baudin, J.-M. Bidart, P. Rougier, V. Lazar, P. Ruffié, J. Ropers, M. Ducreux, F. Troalen, J.-C. Sabourin, E. Comoy, et al. Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 69 - 75. [Abstract] [Full Text]

				J. Korhonen, H. Alfthan, P. Ylostalo, J. Veldhuis, and U.-H. Stenman Disappearance of human chorionic gonadotropin and its {alpha}- and ß-subunits after term pregnancy Clin. Chem., November 1, 1997; 43(11): 2155 - 2163. [Abstract] [Full Text] [PDF]

				L. Liu, D. Leaman, M. Villalta, and R. M. Roberts Silencing of the Gene for the {alpha}-Subunit of Human Chorionic Gonadotropin by the Embryonic Transcription Factor Oct-3/4 Mol. Endocrinol., October 1, 1997; 11(11): 1651 - 1658. [Abstract] [Full Text]

				U.-H. Stenman, L. Unkila-Kallio, J. Korhonen, and H. Alfthan Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping control Clin. Chem., July 1, 1997; 43(7): 1293 - 1298. [Abstract] [Full Text] [PDF]

				P. Chanson, J. Pantel, J. Young, B. Couzinet, J.-M. Bidart, and G. Schaison Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1397 - 1402. [Abstract] [Full Text] [PDF]

				J. Bidart, F Troalen, P Ghillani, N Rouas, A Razafindratsita, C Bohuon, and D Bellet Peptide immunogen mimicry of a protein-specific structural epitope on human choriogonadotropin Science, May 11, 1990; 248(4956): 736 - 739. [Abstract] [PDF]